Sequence-identification of Candida species isolated from candidemia

Authors

1 Department of Medical Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Department of Medical Parasitology and Mycology, School of Medicine; Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

3 Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 Department of Biology, School of Applied Sciences, Imam Hossein University, Tehran, Iran

5 Department of Biology, Ashkezar Branch, Islamic Azad University, Ashkezar, Yazd, Iran

Abstract

Background: Candida species are the most prevalent cause of invasive fungal infections such as candidemia. Candidemia is a lethal fungal infection among immunocompromised patients worldwide. Main pathogen is Candida albicans but a global shift in epidemiology toward non-albicans species have reported. Species identification is imperative for good management of candidemia as a fatal infection. The aim of the study is to identify Candida spp. obtained from candidemia and determination of mortality rate among this population.
Materials and Methods: The study was performed during February 2014 to March 2015 in Tehran, Iran. Two-hundred and four blood cultures were evaluated for fungal bloodstream infection. Identification of isolates was carried out using phenotypic tests and polymerase chain reaction sequencing technique.
Results: Twenty-two out of 204 patients (10.8%) had candidemia. Candida parapsilosis was the most prevalent species (45.4%), followed by C. albicans (31.8%) and Candida glabrata (22.7%). Male to female sex ratio was 8/14.
Conclusions: The emergence of resistant strains of Candida species should be considered by physicians to decrease the mortality of this fatal fungal infection by appropriate treatment.

Keywords

1.
Bar K, Wisplinghoff H, Wenzel RP, Bearman GM, Edmond MB. Systemic inflammatory response syndrome in adult patients with nosocomial bloodstream infections due to enterococci. BMC Infect Dis 2006;6:145.  Back to cited text no. 1
[PUBMED]    
2.
Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: A persistent public health problem. Clin Microbiol Rev 2007;20:133-63.  Back to cited text no. 2
[PUBMED]    
3.
Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: A patient-level quantitative review of randomized trials. Clin Infect Dis 2012;54:1110-22.  Back to cited text no. 3
[PUBMED]    
4.
Arendrup MC, Bruun B, Christensen JJ, Fuursted K, Johansen HK, Kjaeldgaard P, et al. National surveillance of fungemia in Denmark (2004 to 2009). J Clin Microbiol 2011;49:325-34.  Back to cited text no. 4
[PUBMED]    
5.
Pappas PG; Mycoses Study Group. Candidemia in the intensive care unit: Miles to go before we sleep. Crit Care Med 2011;39:884-5.  Back to cited text no. 5
[PUBMED]    
6.
Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1994;271:1598-601.  Back to cited text no. 6
[PUBMED]    
7.
Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Meis JF, Gould IM, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: An 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2007;45:1735-45.  Back to cited text no. 7
[PUBMED]    
8.
Diekema DJ, Messer SA, Brueggemann AB, Coffman SL, Doern GV, Herwaldt LA, et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002;40:1298-302.  Back to cited text no. 8
[PUBMED]    
9.
Chow JK, Golan Y, Ruthazer R, Karchmer AW, Carmeli Y, Lichtenberg D, et al. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis 2008;46:1206-13.  Back to cited text no. 9
[PUBMED]    
10.
Samonis G, Kofteridis DP, Saloustros E, Giannopoulou KP, Ntziora F, Christidou A, et al. Candida albicans versus non-albicans bloodstream infection in patients in a tertiary hospital: An analysis of microbiological data. Scand J Infect Dis 2008;40:414-9.  Back to cited text no. 10
[PUBMED]    
11.
Chi HW, Yang YS, Shang ST, Chen KH, Yeh KM, Chang FY, et al. Candida albicans versus non-albicans bloodstream infections: The comparison of risk factors and outcome. J Microbiol Immunol Infect 2011;44:369-75.  Back to cited text no. 11
[PUBMED]    
12.
Bassetti M, Trecarichi EM, Righi E, Sanguinetti M, Bisio F, Posteraro B, et al. Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagn Microbiol Infect Dis 2007;58:325-31.  Back to cited text no. 12
[PUBMED]    
13.
Velasco E, Bigni R. A prospective cohort study evaluating the prognostic impact of clinical characteristics and comorbid conditions of hospitalized adult and pediatric cancer patients with candidemia. Eur J Clin Microbiol Infect Dis 2008;27:1071-8.  Back to cited text no. 13
[PUBMED]    
14.
Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-17.  Back to cited text no. 14
[PUBMED]    
15.
Pfaller M, Neofytos D, Diekema D, Azie N, Meier-Kriesche HU, Quan SP, et al. Epidemiology and outcomes of candidemia in 3648 patients: Data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004-2008. Diagn Microbiol Infect Dis 2012;74:323-31.  Back to cited text no. 15
[PUBMED]    
16.
Zimbeck AJ, Iqbal N, Ahlquist AM, Farley MM, Harrison LH, Chiller T, et al. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance. Antimicrob Agents Chemother 2010;54:5042-7.  Back to cited text no. 16
    
17.
Lott TJ, Frade JP, Lockhart SR. Multilocus sequence type analysis reveals both clonality and recombination in populations of Candida glabrata bloodstream isolates from U.S. surveillance studies. Eukaryot Cell 2010;9:619-25.  Back to cited text no. 17
    
18.
Cleveland AA, Farley MM, Harrison LH, Stein B, Hollick R, Lockhart SR, et al. Changes in incidence and antifungal drug resistance in candidemia: Results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis 2012;55:1352-61.  Back to cited text no. 18
[PUBMED]    
19.
Diekema D, Arbefeville S, Boyken L, Kroeger J, Pfaller M. The changing epidemiology of healthcare-associated candidemia over three decades. Diagn Microbiol Infect Dis 2012;73:45-8.  Back to cited text no. 19
[PUBMED]    
20.
Nucci M, Queiroz-Telles F, Alvarado-Matute T, Tiraboschi IN, Cortes J, Zurita J, et al. Epidemiology of candidemia in Latin America: A laboratory-based survey. PLoS One 2013;8:e59373.  Back to cited text no. 20
[PUBMED]    
21.
Matsumoto E, Boyken L, Tendolkar S, McDanel J, Castanheira M, Pfaller M, et al. Candidemia surveillance in Iowa: Emergence of echinocandin resistance. Diagn Microbiol Infect Dis 2014;79:205-8.  Back to cited text no. 21
[PUBMED]    
22.
Lotfi N, Shokohi T, Nouranibaladezaei SZ, Nasrolahi Omran A, Kondori N. High recovery rate of non-albicans Candida species isolated from burn patients with candidemia in Iran. Jundishapur J Microbiol 2015;8:e22929.  Back to cited text no. 22
[PUBMED]    
23.
Ghahri M, Mirhendi H, Zomorodian K, Kondori N. Identification and antifungal susceptibility patterns of Candida strains isolated from blood specimens in Iran. Arch Clin Infect Dis 2013;8:e14529.  Back to cited text no. 23